Cevimeline (hydrochloride) (AF102B hydrochloride) 是乙酰胆碱的奎宁环衍生物，是一种选择性和口服活性的毒蕈碱 M1 和 M3 受体激动剂。
| Cas No. | 107220-28-0 |
| 别名 | 盐酸西维美林; AF102B hydrochloride |
| Canonical SMILES | C[C@@H](SC1)O[C@@]21CN3CCC2CC3.Cl |
| 分子式 | C10H17NOS•HCl |
| 分子量 | 235.8 |
| 溶解度 | DMF: 3 mg/ml,DMSO: 5 mg/ml,Ethanol: 5 mg/ml,PBS (pH 7.2): 10 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Cevimeline hydrochloride (AF102B hydrochloride) is a muscarinic M1 and M3 receptor agonist. Cevimeline hydrochloride acts a parasympathomimetic and muscarinic agonist used in the treatment of dry mouth associated with sjogren's syndrome. References:
[1]. Witsell DL, et al. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.Head Neck. 2012 Aug;34(8):1136-42. doi: 10.1002/hed.21894. Epub 2012 Jan 9.
[2]. Ono K, et al. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats.Arch Oral Biol. 2012 Apr;57(4):421-8. Epub 2011 Nov 17.
[3]. Kondo Y, et al.Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na+ content in saliva results from specific and early activation of Na+/H+ exchange.J Pharmacol Exp Ther. 2011 Apr;337(1):267-74. Epub 2011 Jan 14.
[4]. Voskoboynik B, et al.Cevimeline (Evoxac) overdose.J Med Toxicol. 2011 Mar;7(1):57-9.
[5]. Tajiri S, et al. Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations.Int J Pharm. 2010 Jan 4;383(1-2):99-105. Epub 2009 Sep 10. |
m.cnreagent.com